A New Report Published by Research Beam, Titled, “Global Repaglinide Market Outlook 2016-2021”
Research Beam Studies “Repaglinide Market” Report Provides an in-depth Analysis of the current and emerging market trends and dynamics in the global market & for further inquiries, about Global Repaglinide Market with request sample: http://www.researchbeam.com/global-repaglinide-outlook-2016-2021-market/request-sample
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is an oral medication used in addition to diet and exercise for blood sugar control in type 2 diabetes mellitus. The mechanism of action of repaglinide involves promoting insulin release from ?-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the U.S., GlucoNorm in Canada, Surepost in Japan, Repaglinide in Egypt by EIPICO, and NovoNorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma.
This report provides detailed analysis of worldwide markets for Repaglinide from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Repaglinide market and further lays out an analysis of the factors influencing the supply/demand for Repaglinide, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Researchbeam report, Global Repaglinide Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Repaglinide market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Repaglinide market are Novo Nordisk (Denmark), API Polpharma (Poland), Aurobindo Pharma (India), Dr.Reddy`s Laboratories (India), Sumitomo Pharmaceuticals (Japan), Hansoh Pharma (China), Hengrui Pharmaceutical (China), Beilu (China), Beijing Winsunny (China), among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Repaglinide industry has been provided.
Get Discount on Report Purchase: http://www.researchbeam.com/global-repaglinide-outlook-2016-2021-market/purchase-enquiry
Table of Contents
Part 1. Exclusive Summary
Part 2. Methodology
2.1 Research Methodology
2.2 Geographic Scope
2.3 Years Considered
Part 3. Introduction
3.2 Supply Chain Structure
3.2.1 Raw Material Supply
3.2.2 Traders & Distributors
3.2.3 Key Customers
3.3.1 Manufacturing Process
3.3.2 Production Cost
Part 4. Market Landscape
4.1 Global Repaglinide Market Size (Volume) 2011-2016
4.1.2 Global Repaglinide Production
4.1.3 Top 10 Repaglinide Companies (Volume Share)
4.2 Global Repaglinide Market Size (Value) 2011-2016
4.2.2 Global Repaglinide Production Value
4.2.3 Top 10 Repaglinide Companies (Revenue Share)
Enquire About Repaglinide Market – Global Scenario, Industry Outlook, Share, Industry Analysis, Size, Trends and Forecast, 2016 – 2021 Report at: http://www.researchbeam.com/global-repaglinide-outlook-2016-2021-market/enquire-about-report